Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open, Prospective Study of the Safety of GSK Biologicals' Boostrix® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) Administered to a Cohort of Adolescents in a US Health Maintenance Organization (HMO)

NCT00297856 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00297856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00297856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open, Prospective Study of the Safety of GSK Biologicals' Boostrix® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) Administered to a Cohort of Adolescents in a US Health Maintenance Organization (HMO)
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
March 31, 2006
Completion date
December 31, 2006
Enrollment
10,000 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acellular pertussis, diphtheria, tetanus